<table>
<thead>
<tr>
<th>NQF #</th>
<th>Measure</th>
<th>Measure Steward</th>
<th>Level of Analysis</th>
<th>Consensus Agreement / Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Endoscopy &amp; Polyp Surveillance Measures</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0658</td>
<td>Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients</td>
<td>AGA</td>
<td>Clinician</td>
<td>Consensus to include in core set.</td>
</tr>
<tr>
<td>0659</td>
<td>Colonoscopy Interval for Patients with a History of Adenomatous Polyps- Avoidance of Inappropriate Use</td>
<td>AGA</td>
<td>Clinician</td>
<td>Consensus to include in core set.</td>
</tr>
<tr>
<td></td>
<td><strong>PQRS #343</strong> Screen Colonoscopy Adenoma Detection Rate Measure.</td>
<td>ASGE</td>
<td></td>
<td>Consensus to include in core set.</td>
</tr>
</tbody>
</table>
|        | **PQRS #439** Age Appropriate Screening Colonoscopy                      | AGA             | Clinician         | **Consensus to include in core set for measurement at the group level.**  
**Note:** Programs utilizing this measure are not looking for 100% performance. |
|        | **Inflammatory Bowel Disease**                                           |                 |                   |                                                                       |
|        | **PQRS #271** IBD: Preventive Care: Corticosteroid Related Iatrogenic Injury – Bone Loss Assessment* | AGA             | Clinician         | Consensus to include in core set.                                     |
|        | **PQRS #275** IBD: Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy* | AGA             | Clinician         | Consensus to include in core set.                                     |

*Note: For 2015 PQRS, a “global denominator” was added to the IBD Measures Group. AGA intends to submit its IBD measures for NQF-endorsement consideration after there are adequate testing data to meet NQF measure evaluation criteria.*
**Hepatitis C Measures for the Gastroenterology Core Measure Set**

<table>
<thead>
<tr>
<th>NQF #</th>
<th>Measure</th>
<th>Measure Steward</th>
<th>Level of Analysis</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>PQRS #401: Screening for Hepatocellular Carcinoma (HCC) in Patients with Hepatitis C Cirrhosis</td>
<td>AGA</td>
<td>Clinician</td>
<td>Consensus to include in core set.</td>
</tr>
<tr>
<td>N/A</td>
<td>PQRS #400: Hepatitis C: One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk</td>
<td>AMA-PCPI</td>
<td>Clinician</td>
<td>Consensus to include in core set.</td>
</tr>
</tbody>
</table>

**Future Areas for Consideration or Measure Development**

- #0635 - Chronic Liver Disease - Hepatitis A Vaccination / Proof of prior vaccination
- #0034 - Colorectal Cancer Screening - measure needs to retooled for GI specialists as they don't take care of a general population
- Adverse events related to colonoscopy screening (i.e., ER or hospital after a procedure, perforation, hemorrhage etc.)
- Assessing the quality of the colonoscopy:
  - Patient Safety measure: #2539 Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy
  - Consideration of CMS measure under development for Post Colonoscopy Complications
  - "Quality colonoscopy" AGA set of measures
- GERD and cirrhosis measures
- Barrett's Esophagus